Trial Profile
An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Adimlecleucel (Primary)
- Indications Cytomegalic inclusion disorders
- Focus Expanded access; Therapeutic Use
- Sponsors Atara Biotherapeutics
- 04 Apr 2019 Status changed from suspended to completed.
- 09 Jan 2017 New trial record